-
公开(公告)号:US20230134700A1
公开(公告)日:2023-05-04
申请号:US17892553
申请日:2022-08-22
IPC分类号: A61K9/28 , A61K9/20 , A61K9/16 , A61J3/06 , A61K9/00 , A61K31/485 , A61K47/34 , A61K9/24 , A61K45/06 , A61K47/10 , A61J3/10 , B29C43/00 , A61J3/00 , B29C37/00 , B29C43/52 , B29B7/88 , B29C35/04 , B29B7/02 , B29C35/16 , B29C43/02 , B29C71/00
摘要: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
-
2.
公开(公告)号:US11384091B2
公开(公告)日:2022-07-12
申请号:US16900600
申请日:2020-06-12
发明人: Robert Chapman , Lonn S. Rider , Qi Hong , Donald Kyle , Robert Kupper
IPC分类号: A61K31/485 , C07D489/08 , C07D489/02 , A61K9/20 , A61K9/48 , A61K9/14 , C07D489/04
摘要: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
-
公开(公告)号:US11304908B2
公开(公告)日:2022-04-19
申请号:US17027222
申请日:2020-09-21
IPC分类号: A61K9/28 , A61K9/20 , A61K9/16 , A61J3/06 , A61K9/00 , A61K31/485 , A61K47/34 , A61K9/24 , A61K45/06 , A61K47/10 , A61J3/10 , B29C43/00 , A61J3/00 , B29C37/00 , B29C43/52 , B29B7/88 , B29C35/04 , B29B7/02 , B29C35/16 , B29C43/02 , B29C71/00 , B29K71/00 , B29K105/00 , B29L31/00
摘要: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
-
4.
公开(公告)号:US11236098B2
公开(公告)日:2022-02-01
申请号:US17202320
申请日:2021-03-15
发明人: Robert Chapman , Lonn S. Rider , Qi Hong , Robert Kupper , Donald J. Kyle
IPC分类号: A61K31/485 , C07D489/08 , C07D489/02 , A61K9/20 , A61K9/48 , A61K9/14 , C07D489/04
摘要: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
-
5.
公开(公告)号:US20210198268A1
公开(公告)日:2021-07-01
申请号:US17202320
申请日:2021-03-15
发明人: Robert CHAPMAN , Lonn S. RIDER , Qi HONG , Robert KUPPER , Donald J. KYLE
IPC分类号: C07D489/08 , A61K9/20 , A61K9/14 , A61K9/48 , A61K31/485 , C07D489/04 , C07D489/02
摘要: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
-
公开(公告)号:US20210169810A1
公开(公告)日:2021-06-10
申请号:US16931803
申请日:2020-07-17
IPC分类号: A61K9/28 , A61K9/20 , A61K9/16 , A61J3/06 , A61K9/00 , A61K31/485 , A61K47/34 , A61K9/24 , A61K45/06 , A61K47/10 , A61J3/10 , B29C43/00 , A61J3/00 , B29C37/00 , B29C43/52 , B29B7/88 , B29C35/04 , B29B7/02 , B29C35/16 , B29C43/02 , B29C71/00
摘要: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
-
公开(公告)号:US20210000749A1
公开(公告)日:2021-01-07
申请号:US17027307
申请日:2020-09-21
IPC分类号: A61K9/28 , A61K9/20 , A61K9/16 , A61J3/06 , A61K9/00 , A61K31/485 , A61K47/34 , A61K9/24 , A61K45/06 , A61K47/10 , A61J3/10 , B29C43/00 , A61J3/00 , B29C37/00 , B29C43/52 , B29B7/88 , B29C35/04 , B29B7/02 , B29C35/16 , B29C43/02 , B29C71/00
摘要: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
-
公开(公告)号:US10537526B2
公开(公告)日:2020-01-21
申请号:US16229188
申请日:2018-12-21
IPC分类号: A61K9/20 , A61K9/00 , A61K31/439 , A61K31/485 , A61K47/38 , A61K47/36 , A61K47/10 , A61K45/06 , A61K31/167 , A61K31/192 , A61K9/16 , A61K47/26 , A61K31/48 , A61K9/48 , A61K47/08 , A61K9/50 , A61K47/32 , A61K9/08 , A61K9/28 , A61K47/12 , A61K47/34 , A61K9/06 , A61K31/4458 , A61K31/137 , A61K47/14 , A61K9/70 , A61J3/10 , A61K47/02 , A61K9/19 , A61K8/73 , A61K47/20
摘要: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
-
公开(公告)号:US20190161492A1
公开(公告)日:2019-05-30
申请号:US16262683
申请日:2019-01-30
申请人: Purdue Pharma L.P. , The P.F. Laboratories, Inc. , Purdue Pharmaceuticals L.P. , Rhodes Technologies
发明人: Robert CHAPMAN , Lonn S. RIDER , Qi HONG , Donald KYLE , Robert KUPPER
IPC分类号: C07D489/08 , C07D489/04 , A61K9/48 , A61K9/20 , C07D489/02 , A61K31/485 , A61K9/14
CPC分类号: C07D489/08 , A61K9/14 , A61K9/20 , A61K9/2095 , A61K9/48 , A61K9/4833 , A61K31/485 , C07D489/02 , C07D489/04
摘要: In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone.
-
公开(公告)号:US20190110996A1
公开(公告)日:2019-04-18
申请号:US16163076
申请日:2018-10-17
IPC分类号: A61K9/20 , A61K47/32 , A61K9/48 , A61K47/02 , A61K31/137 , A61K31/167 , A61K47/14 , A61K47/08 , A61K9/28 , A61K9/50 , A61K47/36 , A61K31/439 , A61K47/34 , A61K31/192 , A61K8/73 , A61K9/00 , A61K47/20 , A61K9/16 , A61K31/48 , A61K47/12 , A61K9/06 , A61K47/26 , A61K9/70 , A61K47/10 , A61K47/38 , A61K31/4458 , A61K9/08 , A61J3/10 , A61K31/485 , A61K45/06 , A61K9/19
摘要: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
-
-
-
-
-
-
-
-
-